IR@PKUHSC  > 北京大学第一临床医学院
学科主题临床医学
Efficacy and safety of glimepiride as initial treatment in Chinese patients with Type 2 diabetes mellitus
Guo, Xiao-hui1; Lv, Xiao-feng2; Han, Ping3; Zhang, Xiu-zhen4; Yang, Hua-zhang5; Duan, Wen-ruo6; Gao, Yan1
关键词Glimepiride Initial treatment Type 2 diabetes mellitus
刊名CURRENT MEDICAL RESEARCH AND OPINION
2013-03-01
DOI10.1185/03007995.2013.765396
29期:3页:169-174
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Medicine, General & Internal ; Medicine, Research & Experimental
资助者Sanofi (China) Investment Co. Ltd. ; Sanofi ; Sanofi (China) Investment Co. Ltd. ; Sanofi
研究领域[WOS]General & Internal Medicine ; Research & Experimental Medicine
关键词[WOS]PREVALENCE ; SULFONYLUREA ; AGENTS ; NIDDM
英文摘要

Objective:

To investigate the efficacy and safety of glimepiride as initial mono-therapy in type 2 diabetes patients in China.

Methods:

This is a multi-center, open-label, single arm study. A total of 391 subjects were enrolled to receive glimepiride treatment for 16 weeks, the initiation dose was 1 mg/d, with titration to 2 mg/d and 4 mg/d according to the fasting blood glucose (FBG) level measured at each visit. The change in HbA1c, fasting plasma glucose (FPG), 2 h postprandial blood glucose (2hPPG), HOMA-IR, weight, waist circumference and the incidence of hypoglycemia were evaluated. An exploratory analysis was conducted to identify the potential population prone to achieve target glycemic control.

Results:

HbA1c was reduced significantly from 8.6 +/- 1.6% to 6.9 +/- 0.9% (p<0.001); 60.9% of the subjects achieved HbA1c <7% at study endpoint. The reduction in FPG and 2hPPG were 2.3 mmol/L and 4.4 mmol/L (p<0.001) respectively. Insulin resistance was improved significantly with HOMA-IR decreasing from 2.5 +/- 2.3 to 2.2 +/- 1.9 (p=0.009). The incidence of confirmed hypoglycemia (BG <= 3.9 mmol/L) was 3.1%.

Conclusions:

Glimepiride treatment as initial mono-therapy could effectively improve blood glucose control in type 2 diabetic patients, with a favorable safety profile. Lack of control group was the major limitation of this study.

语种英语
资助者Sanofi (China) Investment Co. Ltd. ; Sanofi ; Sanofi (China) Investment Co. Ltd. ; Sanofi
WOS记录号WOS:000314851000002
Citation statistics
Cited Times:5[WOS]   [WOS Record]     [Related Records in WOS]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/62733
Collection北京大学第一临床医学院
作者单位1.Peking Univ, Hosp 1, Beijing 100034, Peoples R China
2.Beijing PLA, Mil Gen Hosp, Beijing, Peoples R China
3.China Med Univ, Shengjing Hosp, Shenyang, Peoples R China
4.Guangdong Gen Hosp, Guangzhou, Guangdong, Peoples R China
5.Qingdao Municipal Hosp, Qingdao, Peoples R China
6.Tongji Univ, Tongji Hosp, Sch Med, Shanghai 200092, Peoples R China
Recommended Citation
GB/T 7714
Guo, Xiao-hui,Lv, Xiao-feng,Han, Ping,et al. Efficacy and safety of glimepiride as initial treatment in Chinese patients with Type 2 diabetes mellitus[J]. CURRENT MEDICAL RESEARCH AND OPINION,2013,29(3):169-174.
APA Guo, Xiao-hui.,Lv, Xiao-feng.,Han, Ping.,Zhang, Xiu-zhen.,Yang, Hua-zhang.,...&Gao, Yan.(2013).Efficacy and safety of glimepiride as initial treatment in Chinese patients with Type 2 diabetes mellitus.CURRENT MEDICAL RESEARCH AND OPINION,29(3),169-174.
MLA Guo, Xiao-hui,et al."Efficacy and safety of glimepiride as initial treatment in Chinese patients with Type 2 diabetes mellitus".CURRENT MEDICAL RESEARCH AND OPINION 29.3(2013):169-174.
Files in This Item:
There are no files associated with this item.
Related Services
Recommend this item
Bookmark
Usage statistics
Export to Endnote
谷歌学术
谷歌学术Similar articles in
[Guo, Xiao-hui]'s Articles
[Lv, Xiao-feng]'s Articles
[Han, Ping]'s Articles
百度学术
百度学术Similar articles in
[Guo, Xiao-hui]'s Articles
[Lv, Xiao-feng]'s Articles
[Han, Ping]'s Articles
必应学术
必应学术Similar articles in
[Guo, Xiao-hui]'s Articles
[Lv, Xiao-feng]'s Articles
[Han, Ping]'s Articles
Terms of Use
No data!
Social Bookmark/Share
All comments (0)
No comment.
 

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.